Patents Examined by Julie Wu
  • Lytic-peptide-Her2/neu (Human Epidermal growth factor Receptor 2) ligand conjugates and methods of use
    Patent number: 10729740
    Abstract: The invention relates to conjugates that bind to Her2/neu, methods of using conjugates that bind to Her2/neu and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies that express Her2/neu.
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: August 4, 2020
    Assignee: Esperance Pharmaceuticals, Inc.
    Inventors: Hector Alila, Carola Leuschner
  • Methods, systems, and compositions for promoting bone growth
    Patent number: 10729810
    Abstract: The present invention relates to novel bone compositions for locally delivering a therapeutic agent to the site of a bone defect. Therapeutic agents may promote repair of the bone defect and/or treat conditions or disorders such as pain, inflammation, cancer, and infection. The compositions include calcium phosphate cements and a demineralized bone matrix or a collagen sponge. The compositions are useful for implantation in a patient at the site of a bone defect.
    Type: Grant
    Filed: July 18, 2014
    Date of Patent: August 4, 2020
    Assignees: CAYMAN CHEMICAL COMPANY, INC, MYOMETRICS LLC
    Inventors: Stephen Douglas Barrett, Joseph Michael Colombo, Bradlee David Germain, Andriy Kornilov, James Bernard Kramer, Adam Uzieblo, Gregory William Endres, Fred Lawrence Ciske, Thomas Allen Owen, James Paul O'Malley
  • Methods and compositions relating to P62 for the treatment and prophylaxis of cancer
    Patent number: 10716837
    Abstract: Provided herein are novel p62 compositions for the prophylaxis and treatment of cancer and related methods. The invention also provides modified p62 compositions that increase the anti-cancer activity of p62.
    Type: Grant
    Filed: November 1, 2016
    Date of Patent: July 21, 2020
    Assignee: CURELAB ONCOLOGY, INC.
    Inventors: Alexander Shneider, Franco Venanzi, Michael Sherman, Victor Shifrin
  • Anti-NKP46 antibodies, toxin conjugates, and therapeutic use of same
    Patent number: 10716864
    Abstract: An affinity binding moiety comprising an antigen recognition region which comprises complementarity determining region (CDR) amino acid sequences as set forth in heavy chain ordered N to C terminus: SEQ ID NOs: 4, 6 and 8, and light chain ordered N to C terminus: SEQ ID NOs: 12, 14 and 16 is disclosed. A pharmaceutical compositions comprising as an active ingredient the affinity binding moiety is also disclosed. Methods of diagnosing, preventing or treating an autoimmune disease or a cancer associated with an expression of NKp46 are also disclosed.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: July 21, 2020
    Assignees: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., UNIVERSITY OF RIJEKA FACULTY OF MEDICINE
    Inventors: Ofer Mandelboim, Stipan Jonjic, Orit Berhani, Ariella Glasner
  • RNA-guided human genome engineering
    Patent number: 10717990
    Abstract: A method of altering a eukaryotic cell is provided including transfecting the eukaryotic cell with a nucleic acid encoding RNA complementary to genomic DNA of the eukaryotic cell, transfecting the eukaryotic cell with a nucleic acid encoding an enzyme that interacts with the RNA and cleaves the genomic DNA in a site specific manner, wherein the cell expresses the RNA and the enzyme, the RNA binds to complementary genomic DNA and the enzyme cleaves the genomic DNA in a site specific manner.
    Type: Grant
    Filed: June 30, 2014
    Date of Patent: July 21, 2020
    Assignee: President and Fellows of Harvard College
    Inventors: Prashant G. Mali, George M. Church, Luhan Yang
  • Methods to detect myocardial injury and uses thereof
    Patent number: 10690681
    Abstract: The present invention provides an accurate and reliable method to detect acute cardiovascular syndromes or disorders and to detect acute cardiovascular syndromes or disorders at earlier time points such that more aggressive interventions can be used in high risk subjects
    Type: Grant
    Filed: March 7, 2016
    Date of Patent: June 23, 2020
    Assignee: Washington University
    Inventors: Walter A. Boyle, Richard Bach
  • Method for the serological diagnosis of rheumatoid arthritis
    Patent number: 10684283
    Abstract: This disclosure relates to the field of diagnostic methods. A new marker antibody for rheumatoid arthritis, as well as a new method for detecting rheumatoid arthritis, is disclosed herein. Also provided herein are means and methods for predicting whether a subject will develop rheumatoid arthritis. This disclosure is based on the discovery that patients with rheumatoid arthritis have antibodies in their circulation that react specifically with citrullinated antibodies. In one aspect, the disclosure, therefore, relates to an antibody comprising a citrulline residue. In another aspect, the disclosure provides a method for the detection of antibodies specific for rheumatoid arthritis in a sample from a subject, wherein the sample is contacted with a citrullinated antibody and wherein it is determined whether the sample comprises antibodies specifically reactive with the citrullinated antibody.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: June 16, 2020
    Assignee: NOVIO TH B.V.
    Inventor: Martinus Hubertus Leonardus Salden
  • Diagnostics of gyneacological diseases, especially epithelial ovarian cancer
    Patent number: 10684285
    Abstract: The present disclosure relates to methods and a kit for diagnosing, prognosing and/or monitoring a gynaecological disease, especially epithelial ovarian cancer, on the basis of altered glycosylation pattern of CA125. More specifically, said altered glycosylation pattern relates to that recognizable by MGL.
    Type: Grant
    Filed: July 4, 2016
    Date of Patent: June 16, 2020
    Assignee: KAIVOGEN OY
    Inventors: Kim Pettersson, Kamlesh Gidwani
  • Dual specific antibodies
    Patent number: 10683348
    Abstract: The invention provides dual specific antibodies and methods of making and using such antibodies. In general, the dual specific antibodies are generated by identification of a monospecific antibody having light chain variable region VL residues that are electrostatic or hydrophobic and altering the nucleic acid sequence encoding one or more solvent accessible residues in the VH of the antibody either alone or in combination with alteration of the nucleic acid sequence encoding the VL of the antibody. The altered VH and the VL are expressed and dual specific antibodies, or antigen-binding fragments thereof, are selected. Exemplary dual specific antibodies are also provided as well as methods of using the antibodies.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: June 16, 2020
    Assignee: Genentech, Inc.
    Inventors: Germaine Fuh, Chingwei V. Lee, Patrick Koenig
  • Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
    Patent number: 10683364
    Abstract: The present invention relates to antibodies and their fragments that are immunoreactive to the mammalian, and more particularly, the human B7-H3 receptor and to uses thereof, particularly in the treatment of cancer and inflammation. The invention thus particularly concerns humanized B7-H3-reactive antibodies and their immunoreactive fragments that are capable of mediating, and more preferably enhancing the activation of the immune system against cancer cells that are associated with a variety of human cancers.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: June 16, 2020
    Assignee: MacroGenics, Inc.
    Inventors: Leslie S. Johnson, Paul A. Moore, Ling Huang, Deryk T. Loo, Francine Zhifen Chen
  • Pharmaceutical products from fungal strains
    Patent number: 10682380
    Abstract: Disclosed herein are compositions comprising an isolated cellulose degrading fungus and pharmaceutical substances produced by the fungus.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: June 16, 2020
    Assignee: Menon Renewable Products, Inc.
    Inventors: Suresh Menon, Samantha S Orchard, Jessica Badger, David Lipson, Sara Guidi, Jagadish C Sircar, Kashinatham Alisala
  • MSI-specific frameshift peptides (FSP) for prevention and treatment of cancer
    Patent number: 10682402
    Abstract: Described is a vaccine for prevention and treatment of cancer characterized by microsatellite instability (MSI). The vaccine contains an MSI-specific frameshift peptide (FSP) generating humoral and cellular responses against tumor cells or a nucleic acid encoding said FSP. The vaccine of the present invention is particularly useful for the prevention/treatment of colorectal cancer, endometrial cancer, gastric cancer or small bowel cancer.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: June 16, 2020
    Assignee: Ruprecht-Karls-Universität Heidelberg
    Inventors: Matthias Kloor, Miriam Reuschenbach, Magnus von Knebel-Doeberitz
  • Immunoassay standards and measurement of clinical biomarkers using intra-assay calibration standards
    Patent number: 10670612
    Abstract: The present invention provides novel compositions and methods for creating quantitative standards to calibrate analytes. These compositions and methods enable the creation of standards and calibrators for analyzing analytes and measuring clinical biomarkers. Also provided are kits comprising the novel compositions for use in assays, for example sandwich immunoassays.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: June 2, 2020
    Assignee: SALADAX BIOMEDICAL
    Inventors: Paul Rhyne, Claudio Mapelli, Oitak Allen Wong, Flora Berisha, Robert John Neely
  • Compositions and methods for inhibition of lineage specific antigens
    Patent number: 10668103
    Abstract: Disclosed herein are methods of administering an agent targeting a lineage-specific cell-surface antigen and a population of hematopoietic cells that are deficient in the lineage-specific cell-surface antigen for immunotherapy of hematological malignancies.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: June 2, 2020
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Siddhartha Mukherjee, Florence Borot, Abdullah Mahmood Ali
  • TEM-1 diagnostic antibodies
    Patent number: 10662251
    Abstract: Described herein are antibodies, and antigen-binding fragments thereof, that are specific for tumor endothelial marker 1 (TEM-1), related polynucleotides, expression vectors, and cells that express the described antibodies. Also provided are methods of using the described antibodies, and antigen-binding fragments thereof, and related kits. Provided herein are also methods for diagnosing TEM-1-expressing cancers (such as melanoma, sarcoma, bladder cancer or colon cancer) using the described antibodies, and antigen-binding fragments thereof. The methods involve determining the amount of TEM-1 in a biological sample derived from a subject and comparing this level with the level of TEM-1 in a known standard or reference sample.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: May 26, 2020
    Assignee: Eisai R&D Managment Co, Ltd.
    Inventor: Daniel John O'Shannessy
  • Cancer methods
    Patent number: 10660955
    Abstract: A method of treating a patient having a cancer in which HER2, HER4, FGFR1, EPHA2 and/or FGFR3 is upregulated and/or in which HER2, HER4, FGFR1, EPHA2 and/or FGFR3 mediated-signaling is upregulated, the method comprising administering to the patient a compound comprising or consisting of an OPCML polypeptide (SEQ ID NO: 1), or a fragment thereof which comprises at least one Ig domain of OPCML, or a variant thereof having at least 90% sequence identity with the OPCML polypeptide or the fragment thereof, or a nucleic acid molecule winch encodes the OPCML polypeptide or fragment or variant thereof.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: May 26, 2020
    Inventor: Hani Gabra
  • Compositions and methods for inhibition of lineage specific antigens
    Patent number: 10660919
    Abstract: Disclosed herein are methods of administering an agent targeting a lineage-specific cell-surface antigen and a population of hematopoietic cells that are deficient in the lineage-specific cell-surface antigen for immunotherapy of hematological malignancies.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: May 26, 2020
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Siddhartha Mukherjee, Florence Borot, Abdullah Mahmood Ali
  • Compositions and methods for immunotherapy
    Patent number: 10654928
    Abstract: The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing at least one of an antigen recognizing receptor and one of a chimeric costimulatory receptor. Methods of using the immunoresponsive cell include those for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: May 19, 2020
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Christopher C. Kloss, Michel Sadelain
  • Antibody for treating autoimmune diseases
    Patent number: 10647769
    Abstract: To provide a novel antibody. Provided is a monoclonal antibody or a binding fragment thereof that binds to domain 3 of human LAG-3 and has one or more of the properties described in (ii) to (v), and the properties described in (i) and (vi) below: (i) having in vitro ADCC activity; (ii) reducing the number of LAG-3 positive cells in vivo in low fucose form; (iii) suppressing experimental autoimmune encephalomyelitis in vivo in low fucose form; (iv) binding to human activated T cells; (v) human LAG-3 binds to human major histocompatibility complex class II molecules in the presence of the antibody or the binding fragment thereof; and (vi) the presence of the antibody or the binding fragment thereof allowing human LAG-3 to exert a human T cell suppression function.
    Type: Grant
    Filed: November 7, 2019
    Date of Patent: May 12, 2020
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Ryuta Mukasa, Kensuke Nakamura, Sumie Muramatsu, Naoyuki Makita
  • Surface treatment for cell culture
    Patent number: 10647953
    Abstract: An article suitable for inducing quasispherical cell clustering is provided. The article comprising: a layer suitable for culturing quasispherical cell clusters, the layer comprising a bulk region comprising an interpenetrating network of at least one predominantly positively charged polyelectrolyte and at least one predominantly negatively charged positive polyelectrolyte, a back surface region, and a front surface region, wherein the front surface region comprises a net negative fixed surface charge density of between about 0.4 micromole per m2 and about 1.5 micromole per m2.
    Type: Grant
    Filed: January 25, 2016
    Date of Patent: May 12, 2020
    Assignee: The Florida State University Research Foundation, Inc.
    Inventors: Joseph B. Schlenoff, Carlos Arias